← Back

Clinical Medicine and Surgery I · Exam 8 — Clin Med Pro Guide

PAJ 5500 Clinical Medicine and Surgery I · Class of 2028

Hematology block · 37 conditions across 3 lectures · Dr. Carter’s Clin Med Pro Study Tip, ten fields per condition

How to use this guide

Dr. Carter’s Clin Med Pro Study Tip (Hypotension deck, slide 7) lists what to learn for every condition. Each card below answers those ten fields:

  1. Name of Condition
  2. Definition
  3. Etiology (cause)
  4. Epidemiology (who)
  5. Risk Factors
  6. Pathology
  7. Clinical Manifestation
  8. Diagnosis
  9. Treatment/Therapy
  10. Mortality ★

Every field comes from the lecture slides only. Where a deck is silent the card says Not covered in the lecture rather than filling the gap from elsewhere (37 of 370 fields in this exam; Mortality alone: 2 of 37). Slide numbers follow each field. Cards open closed; tap one to read it.

The ★ on Mortality is on the original study-tip slide: fill it when a figure exists. A ★ highlighted phrase inside a field is a fact the professor emphasized in the lecture recording, carried over from this exam’s study guide.

Lecture 46 · Cytopenias and Hemochromatosis

Matt Ward, DMSc, MBA, PA-C · 15 conditions · source: Cytopenias_Hemochromatosis_Objectives_Enhanced.pptx

Note: Built from the slides only. Prof. Ward's spoken flags (recording, 12 November) lead each note; the stars also mark the slides' own visual emphasis (bold, asterisks, underline, the slide 26 arrow). Prognosis lines come from the guideline-summary slides 104-107. Points the slides state two ways are not keyed one way: the serum iron of anemia of chronic disease (low on slide 13, up or down on slide 27; tell it from iron deficiency by ferritin and total iron-binding capacity), chloroquine as a G6PD trigger (slide 79) or safe (slide 83 table; out loud he sided with the table, so no antimalarial is keyed), where G6PD sits (membrane on slide 79, inside the cell on slide 77), the total iron-binding capacity of anemia of chronic disease (normal or low on slide 13, decreased on slide 27) and thalassemia reticulocytes (a reticulocytosis on slide 13, a low reticulocyte index on slide 87). Beta thalassemia ancestry (slide 86) and the chorionic villus sampling week (slide 92) are not keyed. The slides give no epidemiology for lead poisoning, B12 deficiency or neutropenia.
Iron deficiency anemia★ Professor emphasized1 not covered

★ Said: "You guys want to know this slide" (slide 15): microcytosis, hypochromia, low ferritin and saturation, high total iron-binding capacity; replace the iron and still correct the underlying cause. Slide emphasis: chronic blood loss is the most common adult cause; asterisked nail, lip and Plummer-Vinson findings; ferritin is an acute phase reactant; ferrous sulfate and its constipation.

Name of Condition
Iron deficiency anemia Slide 9
Definition
A microcytic, hypochromic anemia from too little iron; anemia is a reduction in healthy red blood cells or hemoglobin that lowers oxygen delivery to the tissues Slides 6, 15
Etiology (cause)
★ Chronic blood loss, the most common cause of iron deficiency anemia in adults (gastrointestinal loss and menses); dietary factors (vegan diet, tea drinkers, calcium antacids, medications, particularly proton pump inhibitors); malabsorption (gastric bypass surgery, celiac sprue, food allergies); increased demand (pregnancy, growth in infancy or adolescence) Slide 10
Epidemiology (who)
50% of anemia worldwide; almost 1 million deaths a year, 71% in Africa and Asia, only 1.4% in North America; higher in developing countries. United States: men under 50, 1%; women of childbearing age, 10% (menstrual losses); 9% of children 12 to 36 months are iron deficient and one-third of them develop anemia Slide 11
Risk Factors
Menstruation, gastrointestinal bleeding, vegan diet, tea, calcium antacids, proton pump inhibitors, gastric bypass, celiac sprue, pregnancy, infancy and adolescent growth; low-income families are particularly at risk in the United States Slides 10, 11
Pathology
Not covered in the lecture
Clinical Manifestation
Fatigue, pallor, decreased exercise tolerance, shortness of breath especially with exertion, smooth tongue, pica (common), ★ nail bed changes such as koilonychia (spoon-shaped nails), cheilosis, Plummer-Vinson syndrome Slide 12
Diagnosis
Complete blood count: microcytosis (mean corpuscular volume below 80 fL), hypochromia (low mean corpuscular hemoglobin). Iron panel: reduced ferritin, reduced transferrin saturation, increased total iron-binding capacity. Smear: microcytic, hypochromic cells. ★ Ferritin is an acute phase reactant: a normal or high ferritin does not exclude iron deficiency; consider an erythrocyte sedimentation rate and/or C-reactive protein. Also urinalysis, fecal occult blood test (stool guaiac), consider prothrombin and partial thromboplastin times. Differential: anemia of chronic disease, thalassemia, lead poisoning, zinc deficiency, sideroblastic anemia Slides 13–16
Treatment/Therapy
Treat the underlying cause: oral contraceptive (consider continuous-cycle) for menstrual loss; gastrointestinal bleed: gastroenterology consult for colonoscopy or endoscopy to evaluate for colorectal cancer; stop anticoagulants if anemia is severe (consult cardiology). Iron replacement: ★ ferrous sulfate 325 mg (66 mg elemental iron) once daily or every other day, with at least an as-needed laxative or stool softener for ★ constipation; food lowers side effects and absorption; alternate-day dosing is probably best; or ferrous sulfate 44 mg/5 mL (as elemental iron) once daily in the morning on an empty stomach with a full glass of orange juice. Response: hematocrit halfway to normal in 3 weeks, baseline by 2 months; continue 3 to 6 months after normal values to refill stores. Parenteral iron if intolerant or refractory (most need 1 to 1.5 g). Hematology referral if the diagnosis is not confirmed or there is no response to oral iron Slides 17–21
Mortality ★
Almost 1 million deaths a year worldwide. Prognosis: usually resolves once the cause and iron stores are corrected Slides 11, 106
Anemia of chronic disease★ Professor emphasized

★ Said: "Want to pay attention to this slide?" (slide 23): interleukin 6 raises hepcidin. Slide emphasis: treat the underlying condition is arrowed as most important; ferritin is an acute phase reactant.

Name of Condition
Anemia of chronic disease (anemia of chronic inflammation) Slides 22–23
Definition
Anemia caused by any inflammatory condition; initially resembles iron deficiency anemia Slide 23
Etiology (cause)
Any inflammatory condition: infection, autoimmune disease, neoplasm Slide 23
Epidemiology (who)
The second most common anemia; any age; about 1 million people older than 65 in the United States Slide 24
Risk Factors
Older age (more chronic inflammatory disease) Slide 24
Pathology
Multifactorial: inflammatory cytokines, in particular interleukin-6, upregulate hepcidin, which blocks iron absorption; systemic inflammation inhibits renal erythropoietin production; likely direct inflammatory marrow suppression Slide 23
Clinical Manifestation
Similar to iron deficiency anemia; resembles the causative condition Slide 24
Diagnosis
Same labs as iron deficiency; erythrocyte sedimentation rate and/or C-reactive protein if inflammation is not apparent. Ferritin normal or increased (a ferritin below 30 ng/mL, 67 pmol/L, means coexistent iron deficiency); total iron-binding capacity decreased (slide 27; normal or low on slide 13); reticulocytes usually decreased; mean corpuscular volume normal or low. Serum iron: low on slide 13, up or down on slide 27 Slides 13, 25, 27
Treatment/Therapy
★ Treat the underlying condition (most important); may benefit from erythropoietin (epoetin alfa, Procrit); FDA-approved for hemoglobin below 10 g/dL and anemia due to rheumatoid arthritis, inflammatory bowel disease, hepatitis C, zidovudine therapy in HIV, myelosuppressive chemotherapy of solid malignancy, or chronic kidney disease; may need parenteral iron; hematology referral not usually needed Slide 26
Mortality ★
Prognosis: can persist while the underlying disease is active Slide 106
Sideroblastic anemia
Name of Condition
Sideroblastic anemia Slides 28–29
Definition
Anemia defined by ring sideroblasts in the bone marrow: iron-containing mitochondria forming a basophilic ring around the nucleus Slide 32
Etiology (cause)
Hereditary (usually X-linked); acquired (usually myelodysplastic syndrome); acquired and reversible (alcohol, drugs such as isoniazid and chlorambucil, copper deficiency, hypothermia, lead poisoning). Modern classification: dyserythropoiesis (hypohepcidinemia) or transfusion-dependence (myelodysplastic syndrome, thalassemia) Slides 29–30
Epidemiology (who)
Rare; about two-thirds of cases present in males in early childhood or adolescence, one-third in young to middle-aged females; can occur at any age Slide 30
Risk Factors
Alcohol, isoniazid, chlorambucil, copper deficiency, hypothermia, lead exposure, myelodysplastic syndrome Slide 29
Pathology
Excess total body iron; iron-laden mitochondria ring the nucleus Slide 32
Clinical Manifestation
No specific features other than those of anemia; usually moderate, hematocrit 20 to 30% Slide 31
Diagnosis
Variable microcytosis and hypochromia; dimorphic smear (microcytic, normal and macrocytic cells); increased serum iron, transferrin saturation and ferritin; increased zinc if caused by copper deficiency; bone marrow aspirate with ring sideroblasts (the defining feature) Slide 32
Treatment/Therapy
Remove the offending agent if acquired; red cell transfusion if severe; poor response to recombinant erythropoietin; occasional response to oral pyridoxine (50 to 200 mg/day); luspatercept for myelodysplastic syndrome with ring sideroblasts; hematology referral for diagnostic or transfusion support Slide 33
Mortality ★
Prognosis: variable; clonal forms may require continued follow-up Slide 106
Lead poisoning (plumbism)2 not covered
Name of Condition
Lead poisoning (plumbism) Slide 34
Definition
Lead toxicity causing a microcytic, hypochromic anemia Slide 34
Etiology (cause)
Industrial exposure, gasoline sniffing, lodged bullets, cooking utensils containing lead, lead-based paint chips, contaminated water (Flint water crisis) Slide 34
Epidemiology (who)
Not covered in the lecture
Risk Factors
The exposures listed under etiology Slide 34
Pathology
Basophilic stippling: an abnormal collection of nucleic acids in the cells Slide 34
Clinical Manifestation
Neurologic system most vulnerable: irritability, behavioral changes, peripheral neuropathy. Gastrointestinal: abdominal colic, nausea and constipation, occasionally diarrhea. May be a lead line in the gums Slides 35–36
Diagnosis
Microcytic, hypochromic anemia with basophilic stippling on the smear; treatment is based on the lead level Slides 34–35
Treatment/Therapy
Stop exposure; treatment based on lead level; severe cases with neurologic effects: chelating agents (succimer (Chemet), dimercaprol, ethylenediaminetetraacetic acid (EDTA)) Slide 35
Mortality ★
Not covered in the lecture
Megaloblastic anemia: folate deficiency1 not covered
Name of Condition
Megaloblastic anemia (folate deficiency) Slides 37–39, 42
Definition
A macrocytic anemia (mean corpuscular volume above 100 fL) with megaloblasts (early red cell precursors), macro-ovalocytes and hypersegmented neutrophils; caused by vitamin B12 or folate deficiency Slides 38–39
Etiology (cause)
Folate: dietary (impoverished, indigent, alcohol use disorder, elderly); increased demand (pregnancy); impaired absorption (proximal small bowel); drugs (methotrexate, 5-fluorouracil, hydroxyurea, phenytoin, metformin) Slide 42
Epidemiology (who)
Not covered in the lecture
Risk Factors
Poverty, alcohol use disorder, older age, pregnancy, proximal small bowel disease, the drugs listed Slide 42
Pathology
Impaired DNA synthesis causes nuclear-cytoplasmic asynchrony and impaired hematopoiesis; granulocytes and megakaryocytes affected to a lesser degree Slide 39
Clinical Manifestation
Findings of all anemias: fatigue, pallor, headache; dyspnea and heart failure if severe Slide 45
Diagnosis
Complete blood count: red cells, hemoglobin, hematocrit down; mean corpuscular volume up; mean corpuscular hemoglobin and its concentration normal to slightly up; red cell distribution width up; reticulocytes vary. B12 and folate levels first (not very sensitive), smear; if borderline: homocysteine (needs both B12 and folate) and methylmalonic acid (elevated in B12 deficiency but NOT folate deficiency). Non-megaloblastic macrocytosis (alcohol or drug, hypothyroidism, liver failure, marrow dysplasia) usually stays below 115 fL Slides 38, 40–41, 47
Treatment/Therapy
Before replacing folate, evaluate for B12 deficiency (otherwise labs improve but permanent neurologic symptoms may worsen); folic acid 1 mg orally or parenterally daily for 1 to 2 weeks Slide 49
Mortality ★
Prognosis: counts improve with treatment Slide 106
Vitamin B12 deficiency and pernicious anemia★ Professor emphasized2 not covered

★ Said: "This slide is definitely one that you guys want to pay attention to" (slide 47): methylmalonic acid is for B12 only, not folate. Slide emphasis: pernicious anemia is the most frequent cause; burning of the hands and feet; homocysteine and methylmalonic acid are bold.

Name of Condition
Vitamin B12 (cobalamin) deficiency; pernicious anemia Slides 43–44
Definition
Megaloblastic, macrocytic anemia from too little B12; pernicious anemia is the autoimmune form against parietal cells and/or intrinsic factor Slides 43–44
Etiology (cause)
★ Pernicious anemia, the most frequent cause of B12 deficiency Slide 44
Epidemiology (who)
Not covered in the lecture
Risk Factors
Not covered in the lecture
Pathology
Absorption: peptic digestion frees B12; intrinsic factor from parietal cells binds it and protects it; the complex binds cubilin in the distal ileum; B12 binds transcobalamin and is stored in the liver (about 3 to 4 years or more). Pernicious anemia: autoimmune attack causes gastric mucosal atrophy and increased gastric cancer risk. B12 deficiency demyelinates the dorsal and lateral spinal cord tracts Slides 43–45
Clinical Manifestation
Anemia findings (fatigue, pallor, headache; dyspnea and heart failure if severe); glossitis, oral ulcers. Distinguishing: neurologic findings: neuropsychiatric changes (depression, irritability, insomnia, cognitive slowing, dementia); symmetric numbness, tingling, ★ burning to hands and feet (stocking-and-glove distribution); then unsteady gait and loss of position sense; may or may not improve with B12 Slides 45–46
Diagnosis
B12 and folate levels first (not very sensitive) and smear; if borderline: ★ homocysteine (needs both) and ★ methylmalonic acid (elevated in B12 but not folate deficiency). Pernicious anemia: anti-intrinsic factor antibodies (specific, not sensitive); anti-parietal cell antibodies (neither sensitive nor specific); gastric biopsy may show chronic atrophic gastritis; in reality a megaloblastic picture that corrects with B12 is the usual pathway (parenteral B12 trial) Slides 47–48, 50
Treatment/Therapy
B12 1000 mcg subcutaneously or intramuscularly weekly for 3 weeks, or oral cobalamin 1000 to 2000 mcg daily; evaluate for B12 deficiency before replacing folate Slide 49
Mortality ★
Prognosis: counts improve; delayed B12 treatment may leave neurologic deficits; increased risk of gastric cancer in pernicious anemia Slides 44, 106
Anemia of chronic kidney disease1 not covered
Name of Condition
Anemia of chronic kidney disease (anemia due to renal failure) Slides 51–52
Definition
A normocytic anemia of chronic kidney disease, primarily from decreased erythropoietin Slide 52
Etiology (cause)
Primarily, but not completely, decreased erythropoietin; inflammation and hepcidin restrict available iron Slides 52–53
Epidemiology (who)
Extremely common in chronic kidney disease; incidence rises as glomerular filtration rate declines; almost universal in dialysis patients Slide 52
Risk Factors
Declining glomerular filtration rate; dialysis Slide 52
Pathology
Inappropriately low erythropoietin response; iron-restricted erythropoiesis Slide 53
Clinical Manifestation
Not covered in the lecture
Diagnosis
Complete blood count: red cells, hemoglobin, hematocrit down; mean corpuscular volume, mean corpuscular hemoglobin and its concentration normal; red cell distribution width up; reticulocytes down. Order complete blood count, reticulocyte count, ferritin and transferrin saturation; assess other causes. A low transferrin saturation may mean iron-restricted erythropoiesis despite a normal or high ferritin Slides 52–53
Treatment/Therapy
Correct iron deficiency; consider oral or intravenous iron and an erythropoiesis-stimulating agent based on chronic kidney disease stage, hemoglobin and risk; ferric pyrophosphate citrate (Triferic) in the dialysate replaces the 5 to 7 mg of iron lost each hemodialysis. Follow-up: monitor hemoglobin, iron and blood pressure; nephrology for advanced disease, erythropoiesis-stimulating agent decisions or uncertainty Slides 21, 53, 106
Mortality ★
Prognosis: often chronic; may improve with iron or an erythropoiesis-stimulating agent Slide 106
Aplastic anemia
Name of Condition
Aplastic anemia Slides 54–55
Definition
Pancytopenia (loss of red cells, platelets and white cells) with loss of hematopoietic stem cells, the defining feature Slide 55
Etiology (cause)
Autoimmune; direct stem cell injury (drugs, chemicals, radiation); viral infections; genetic causes. Drugs and agents: cytotoxic or chemotherapeutic drugs (not aplastic anemia if an expected effect), chloramphenicol, ionizing radiation, toxins (benzene, pesticides). Clonal: paroxysmal nocturnal hemoglobinuria, myelodysplastic syndrome, acute myeloid leukemia. Inherited: Fanconi anemia (diagnosed in childhood) Slides 56–57
Epidemiology (who)
Half of cases in the first three decades, with a small peak in childhood and a second between ages 20 and 25; male-to-female ratio about 1:1; 0.6 to 6.1 cases per million Slide 55
Risk Factors
Chloramphenicol, cytotoxic drugs, ionizing radiation, benzene, pesticides, viral infection, inherited conditions (Fanconi anemia) Slides 56–57
Pathology
Drugs, chemicals, viruses or mutations can alter the hematopoietic stem cells and predispose them to autoimmune destruction Slide 56
Clinical Manifestation
Manifestations of pancytopenia: recurrent infections (neutropenia); bleeding, petechiae, purpura (thrombocytopenia); fatigue, pallor Slide 58
Diagnosis
Bone marrow biopsy is required for diagnosis and to exclude other causes Slide 58
Treatment/Therapy
Urgent or emergent hematology/oncology consultation; bone marrow transplant; infection and bleeding precautions Slides 58, 106
Mortality ★
Five-year survival above 75% after bone marrow transplant from a suitable donor; most untreated patients die within one year from complications. Prognosis depends on severity and response to treatment Slides 55, 106
Leukopenia and neutropenia2 not covered
Name of Condition
Leukopenia and neutropenia Slide 59
Definition
Leukopenia is a low total white blood cell count; neutropenia is defined by the absolute neutrophil count Slide 59
Etiology (cause)
Viral illness, medications or chemotherapy, autoimmune disease, nutrient deficits, marrow pathology Slide 59
Epidemiology (who)
Not covered in the lecture
Risk Factors
Infection risk rises with severity, duration and impaired immune status Slide 60
Pathology
Not covered in the lecture
Clinical Manifestation
Profound neutropenia may have subtle findings; fever with an absolute neutrophil count below 500 is an emergency Slide 60
Diagnosis
Absolute neutrophil count = white count x (neutrophils + bands)% / 100. Mild 1,000 to 1,500; moderate 500 to 999; severe below 500 cells/microliter. Repeat complete blood count with differential, review the trend and smear, check other cell lines. Escalate to hematology for persistent or unexplained severe neutropenia, other cytopenias or an abnormal smear Slide 59
Treatment/Therapy
Fever with an absolute neutrophil count below 500 (or expected to fall below 500): prompt assessment, vitals, targeted examination, cultures, empiric antipseudomonal antibiotics without delay. Chronic: stop an offending drug, correct deficiencies, granulocyte colony-stimulating factor for selected patients. Education: report fever or rigors promptly; monitor counts Slide 60
Mortality ★
Prognosis: transient viral leukopenia often resolves after recovery; persistent or severe neutropenia carries greater infection risk and may indicate marrow disease Slide 60
Autoimmune hemolytic anemia★ Professor emphasized1 not covered

★ Slide emphasis: autoimmune hemolytic anemia carries an increased risk of venous thromboembolism (bold); hemolysis labs bilirubin, haptoglobin, lactate dehydrogenase, schistocytes and jaundice are bold.

Name of Condition
Autoimmune hemolytic anemia Slide 71
Definition
Hemolytic anemia (shortened red cell survival from premature destruction) caused by antibody against the red cell membrane Slides 61, 71
Etiology (cause)
Primary (de novo antibody production; almost always IgG) or secondary: viruses (human immunodeficiency virus, hepatitis, Epstein-Barr virus, SARS-CoV-2); autoimmune disorders (lupus, rheumatoid arthritis, scleroderma, ulcerative colitis); lymphoproliferative disorders (leukemia, lymphoma, multiple myeloma); pregnancy. Transfusion reaction is also immune-mediated Slides 65, 71
Epidemiology (who)
Not covered in the lecture
Risk Factors
The secondary causes listed Slide 71
Pathology
Extracorpuscular, immune-mediated hemolysis; hemolytic anemias share a shorter red cell life span, compensatory erythropoiesis (marrow hyperplasia, reticulocytosis) and retention of breakdown products Slides 63, 65
Clinical Manifestation
Anemia symptoms (fatigue, shortness of breath, chest pain, pallor; severe: high-output heart failure, shock); differentiating: ★ jaundice, splenomegaly, joint pain, hematuria; ★ increased risk of venous thromboembolism Slides 70, 73
Diagnosis
Hemolysis labs: complete blood count, reticulocyte count, ★ bilirubin (unconjugated greater than conjugated; jaundice above 2.0 mg/dL), ★ lactate dehydrogenase up, ★ haptoglobin decreased or absent (intravascular), urinalysis, smear (★ schistocytes). Direct antiglobulin (Coombs) test: positive when the washed red cells carry IgG or complement. Consider D-dimer and bilateral leg ultrasound for deep vein thrombosis or pulmonary embolism Slides 66–69, 72–73
Treatment/Therapy
Consider immediate stabilization if hemoglobin below 6, a rapid decline, or instability; contact the blood bank. Rule out secondary causes. Glucocorticoids initially (e.g., prednisone 60 to 100 mg daily); rituximab (anti-CD20); other: immunosuppressants, splenectomy. Venous thromboembolism prophylaxis for inpatients, consider for outpatients Slides 73–74
Mortality ★
Prognosis: relapse may occur; outcome depends on cause and response Slide 107
G6PD deficiency★ Professor emphasized

★ Said: "Be familiar with Heinz bodies, what they are, what they represent" (slides 77-78); hemolysis is intravascular and extravascular. Slide emphasis: fava beans and acute hemolytic anemia are bold. Antimalarials: slide 79 lists chloroquine as a trigger, the slide 83 table as safe, and he said "don't just assume all anti-malarial medications carry that same risk", so no antimalarial is keyed.

Name of Condition
Glucose-6-phosphate dehydrogenase (G6PD) deficiency Slide 76
Definition
The most common genetic disorder of erythrocytes: an enzyme deficiency that leaves red cells open to oxidative damage, causing ★ acute hemolytic anemia on oxidative stress Slides 76, 79
Etiology (cause)
X-linked recessive. Common triggers: ★ fava beans, naphthalene (mothballs), antimalarials (some; Prof. Ward said chloroquine does not carry the same risk), nitrofurantoin, trimethoprim-sulfamethoxazole (Bactrim), methylene blue, phenazopyridine, quinolones Slides 76, 79
Epidemiology (who)
200 to 400 million people. Prevalence: Kurdish Jews 60 to 70%; Sardinians 4 to 35%; Nigerians 22%; Thai people 17%; American Black people 11 to 12%; Brazilian Black people 8%; Greeks 6%; South China about 6%; India 3%; Japanese and Koreans 0 to 1% Slides 76, 80
Risk Factors
Male sex (X-linked recessive; carrier females have two red cell populations and are generally unaffected); exposure to the oxidant triggers Slides 76, 79
Pathology
G6PD is needed in the glutathione pathway; without reduced glutathione, oxidative stress forms Heinz bodies inside the red cell; splenic macrophages remove them by taking a chunk of the cell (bite cells); intravascular and extravascular hemolysis Slides 77–78
Clinical Manifestation
No symptoms until oxidative stress; drug-induced hemolysis is acute, of variable severity, after a lag of 2 to 3 days: abdominal pain, jaundice, dark urine, splenomegaly Slide 81
Diagnosis
Labs consistent with hemolytic anemia; during an attack the smear may show Heinz bodies and bite cells; confirmed by a low G6PD level roughly 8 weeks after an attack Slide 82
Treatment/Therapy
Avoid the trigger ("don't eat that"); hydrate; transfuse if needed; splenectomy only for recurrent attacks. Education: avoid oxidative triggers; seek care for jaundice or dark urine Slides 82, 107
Mortality ★
Prognosis: usually favorable with trigger avoidance Slide 107
Thalassemia★ Professor emphasized

★ Said: "Did I tell you guys to pay attention to slide 88?" (thalassemia labs). Slide emphasis: the globin imbalance line is bold; iron overload is bold and underlined.

Name of Condition
Thalassemia (alpha and beta) Slides 84–85
Definition
A hemoglobinopathy from mutations causing deficient synthesis of alpha or beta globins Slide 85
Etiology (cause)
Inherited mutations of the globin genes (4 alpha, 2 beta); the phenotype depends on how many are mutated, from silent carrier (one alpha gene lost) to incompatible with life Slide 89
Epidemiology (who)
Alpha thalassemia: Southern China, Malaysia, Thailand, Mediterranean region; mild forms in African origin. Asian ancestry often has the alpha thalassemia 1 trait (both deletions on one side, higher risk of hydrops fetalis); African ancestry more often the alpha thalassemia 2 trait (one deletion on each side) Slide 86
Risk Factors
Family history (preconception testing and counseling available) Slide 88
Pathology
★ Imbalance in expression leads to accumulation and precipitation of globin subunits, causing red cell destruction in the spleen; most erythroblasts die in the marrow Slide 85
Clinical Manifestation
Variable by mutation: hemolytic anemia, ★ iron overload, splenomegaly, extramedullary hematopoiesis, jaundice, skeletal changes Slide 87
Diagnosis
Generally low hemoglobin, mean corpuscular volume, mean corpuscular hemoglobin and reticulocyte index (marrow failure); Coombs negative (slide 87); slide 13 adds more microcytosis for the hemoglobin level with a normal or high red cell count, and a reticulocytosis, against the low reticulocyte index of slide 87. Complete blood count, iron studies, reticulocyte count; hemoglobin electrophoresis; gene testing Slides 13, 87–88
Treatment/Therapy
Supportive: transfusion when absolutely necessary (can worsen iron overload); folic acid; genetic counseling. Hematology for severe forms; iron monitoring Slides 89, 107
Mortality ★
Prognosis: trait often mild; severe forms need lifelong monitoring; the most severe genotype is incompatible with life Slides 89, 107
Sickle cell anemia
Name of Condition
Sickle cell anemia (sickle cell disease) Slide 90
Definition
A hemoglobinopathy in which hemoglobin S (two alpha and two mutant beta globins) polymerizes under low oxygen tension and forms a sickle shape Slide 90
Etiology (cause)
Mutation of a beta globin gene Slide 90
Epidemiology (who)
Distribution follows the malaria belt; heterozygous carriers (HbAS) are 90% less likely to have severe malaria Slide 91
Risk Factors
Parents carrying the mutation (preconception screening); reactive lung disease increases the risk of acute chest syndrome Slides 92, 94
Pathology
Polymerized HbS sickles red cells, causing microvascular occlusion and infarction of any tissue with vascular beds; symptoms begin around 5 months of age as fetal hemoglobin gives way to HbS; fetal hemoglobin of 10 to 20% seems to lessen severity Slides 90, 92–93, 97
Clinical Manifestation
Anemia almost universal (hematocrit 15 to 30%); pain crisis (acute pain, tenderness, anxiety, tachycardia); splenic infarct, aseptic necrosis of the femoral or humeral heads, retinopathy, kidney disease; leg ulcers; pediatric stroke (300 times unaffected children; 25% have a stroke by 45); priapism; susceptibility to encapsulated bacteria. Infants: failure to thrive, pain, anemia, splenomegaly, chronic infections, swelling of the extremities. Acute chest syndrome: chest pain, fever, shortness of breath, hypoxemia, new infiltrates on chest X-ray Slides 92–95
Diagnosis
Four screening periods: preconception, prenatal (chorionic villus sampling), neonatal (all 50 states; missed cases usually present within two years), post-natal Slide 92
Treatment/Therapy
Hydroxyurea raises fetal hemoglobin and reduces vaso-occlusive events; vaccinations, indicated childhood penicillin prophylaxis, infection education; urgent assessment for fever, chest pain or hypoxemia, new neurologic deficit; transfusion or exchange for selected severe events (watch alloimmunization and iron loading); hematology follow-up, organ surveillance, consideration of curative therapies Slides 98, 107
Mortality ★
Acute chest syndrome is the leading cause of death, with more than 10% mortality in adults. Prognosis: lifelong disease; prevention reduces complications Slides 94, 107
Hemoglobin C and hemoglobin SC disease5 not covered
Name of Condition
Hemoglobin C; hemoglobin SC disease (sickle cell SC) Slide 96
Definition
Hemoglobin C comes from a different beta globin mutation and does not polymerize; hemoglobin SC disease combines one beta-C with one beta-S globin Slide 96
Etiology (cause)
A different mutation in the beta globin gene; SC = inheriting the C and the S mutations Slide 96
Epidemiology (who)
Not covered in the lecture
Risk Factors
Not covered in the lecture
Pathology
HbC does not polymerize Slide 96
Clinical Manifestation
Hemoglobin SC disease generally has a course between sickle cell anemia and sickle cell trait Slide 96
Diagnosis
Not covered in the lecture
Treatment/Therapy
Not covered in the lecture
Mortality ★
Not covered in the lecture
Hemochromatosis (primary and secondary)
Name of Condition
Hemochromatosis (iron overload), primary and secondary Slides 99–100
Definition
Excess iron deposition throughout the body Slide 100
Etiology (cause)
Primary: autosomal recessive mutation of genes that control iron absorption. Secondary: excessive iron supplementation, chronic liver disease, anemia (parenteral iron overload; transfusion-related overload in children) Slides 100, 105
Epidemiology (who)
HFE hemochromatosis usually presents in adults Slide 105
Risk Factors
Family history (first-degree relatives); iron supplements and excessive alcohol Slide 104
Pathology
Iron deposition raises oxidative stress, causing fibrosis and organ dysfunction; liver, heart, joints, endocrine organs and skin most affected; pituitary iron causes hypogonadotropic hypogonadism Slides 100, 102
Clinical Manifestation
Asymptomatic early; fatigue; skin bronzing (face, neck, groin, extensor forearms and lower legs); joint pain, especially the second and third metacarpophalangeal joints and knees; cardiomyopathy, chest pain, dyspnea on exertion; decreased libido, impotence, amenorrhea, small testes, gynecomastia, reduced body hair Slides 100–102
Diagnosis
Iron panel: ferritin below 300 micrograms/L and transferrin saturation below 45% means no iron overload (ferritin is an acute phase reactant: read the whole picture). Liver biopsy with Prussian blue: primary shows hepatic iron sparing the Kupffer cells until later; secondary (parenteral overload) shows iron predominantly in Kupffer cells. Consider HFE testing with elevated transferrin saturation or ferritin; offer first-degree relative screening Slides 103–104
Treatment/Therapy
Primary: therapeutic phlebotomy with ferritin-guided follow-up. Secondary: treat the cause; consider chelation when phlebotomy is unsuitable. Avoid iron supplements and excessive alcohol; individualize dietary advice Slides 104, 107
Mortality ★
Early treatment can prevent organ damage; assess fibrosis and monitor cirrhosis for liver cancer; established cirrhosis may persist Slides 104, 107

Lecture 49 · Hematologic Malignancies Part I

Nicole Gannon, PA-C · 8 conditions · source: 49. Hematologic Malignancies Part I - Gannon.pptx

Note: Built from the slides only. Prof. Gannon's spoken flags (recording, 18 November) lead each note; the stars also mark the slides' own visual emphasis (bold, underline). The deck splits the syllabus differently: this lecture teaches ALL and AML (syllabus Hematological Malignancies 1) and MDS, the myeloproliferative neoplasms and CML (syllabus Hematologic Malignancies II); lymphoma, CLL and myeloma are Lecture 50, and secondary polycythemia is on neither deck. Points the slides state two ways are not keyed one way: "the most common leukemia" (AML on slide 31, CLL in Lecture 50, CML 15-20% on slide 58), the ALL ages (under 15 and peak ~50 on slide 18; under 5 and over 50 on slide 21), children's and adults' ALL survival (>90% vs ~90%; ~30-40% vs ~40%), and the wording for stopping TKIs (major molecular response on slide 63, remission on slide 66). Spoken numbers that differ from the slides (chronic phase "five to 6%" blasts, blast phase ">20%", stopping after 3 or 5 years) are not used; the slides' are. The joke protocol slides 26 and 39 are excluded. The slides give no diagnostics for myelofibrosis and no epidemiology for the MPNs beyond "rare".
Acute lymphoblastic leukemia (ALL)★ Professor emphasized

★ Said: "Remember that ALL is associated with this BCR-ABL mutation ... chromosome nine and 22. Write it down" (slide 20); "remember ALL in children and then older adults" (bimodal, slide 18); "20% or greater blast in the bone marrow" (slide 25); the lumbar puncture is "the big one" because CNS leukemia is common in ALL. Slide emphasis: most common malignancy under 15 (underlined); flow cytometry and bone marrow biopsy (underlined); Ph+ ALL = TKI + chemotherapy (bold).

Name of Condition
Acute lymphoblastic leukemia (ALL) Slides 17–18
Definition
A leukemia originating with the lymphoid progenitor/stem cells: very immature cells with a rapid ability to proliferate; ★ defined by blast cells of lymphoid origin >= 20% in bone marrow Slides 18, 25
Etiology (cause)
Mutagenesis at the lymphoblast stage, at various stages of differentiation into B or T lymphocytes. Children: often excess chromosome copies (hyperdiploidy, favorable prognosis). Adults: ★ the most common mutation is BCR-ABL, from translocation of chromosomes 9 and 22 (the Philadelphia chromosome). One-third of adult and pediatric patients have no chromosome abnormalities (need mutation analysis; relatively favorable) Slides 19–20
Epidemiology (who)
★ Bimodal distribution: the most common malignancy under the age of 15 (United States 5-year survival >90%); adult peak incidence around 50 years of age. Slide 21: children under 5 and adults over age 50; male gender Slides 18, 21
Risk Factors
Radiation exposure (prior radiation for cancer treatment; atomic bomb exposure in Japan); chemical exposures (benzene, certain chemotherapies); viral infections (EBV (Epstein-Barr virus), HTLV-1 (human T-lymphotropic virus type 1), Caribbean countries); genetic syndromes (Down syndrome, Fanconi anemia, others; ?family history); age (children under 5, adults over 50); male gender Slide 21
Pathology
B-cell precursor ALL often presents in a leukemic phase (primarily blasts and marrow involvement); T-cell ALL is rarer, usually with lymphoma-like characteristics, and may involve the thymus; subtype lymphoblastic lymphoma (immature, aggressive, more lymphoma features). Often diffuse marrow and peripheral blood involvement, in contrast to aggressive lymphomas (nodal or extranodal, minimal marrow) Slides 19, 25
Clinical Manifestation
Symptoms of excessive blast production and lymphoid (nodal) characteristics. Anemia: fatigue, weakness, lightheadedness, shortness of breath, pale skin. Thrombocytopenia: bruising (often petechiae or purpura), bleeding. Ineffective white cells: infections. ★ B-symptoms: weight loss, fever, night sweats, loss of appetite. >50% present with lymphadenopathy, hepatomegaly or splenomegaly. Bone or joint pain from excessive marrow production. Mediastinal mass on chest X-ray in T-cell ALL Slide 22
Diagnosis
Labs: anemia, thrombocytopenia, leukopenia or marked leukocytosis (white count often > 30K; 30% with neutropenia). Confirmed by ★ flow cytometry and bone marrow biopsy: flow identifies the markers and B-cell or T-cell nature; biopsy shows marrow infiltration and allows chromosome and mutation testing. Also imaging, counts, electrolytes, coagulation and ★ lumbar puncture (central nervous system (CNS) involvement is an adverse risk factor). ★ Lymphoid blasts >= 20% in bone marrow. Cytogenetics and mutation analyses for prognosis. Differential: acute myeloid leukemia (AML); chronic lymphocytic leukemia (CLL), aggressive lymphomas; hairy cell leukemia; lymphoblastic lymphoma (hard to tell apart, treated similarly); atypical lymphocytosis of mononucleosis or pertussis (flow cytometry shows ALL is clonal) Slides 22–25
Treatment/Therapy
Philadelphia chromosome-negative: pediatric-like regimens usually for patients < 40 (intensive chemotherapy with induction, consolidation and maintenance; chemotherapy, steroids, often targeted agents); older adults may need therapy changes and dose adjustments. ★ Philadelphia chromosome-positive: tyrosine kinase inhibitors (TKI) + chemotherapy. Allogeneic stem cell transplant where feasible for adverse risk or relapsed ALL. Referral to and management by a hematologist/oncologist (ideally an ALL specialist); most are admitted for work-up and treatment; frequent follow-up and life-long surveillance; clinical trials where feasible Slides 27, 29
Mortality ★
Often positive, particularly for children: five-year overall survival ~90% under 15, with intensive chemotherapy for 2-5 years. Adults: five-year overall survival historically ~40%, cure rate decreasing with age (outcomes poor over 40); improving with immunotherapies. central nervous system involvement is an adverse risk factor Slides 18, 25, 28
Acute myeloid leukemia (AML)★ Professor emphasized

★ Said: "Highlight, star, underline ... Auer rods ... pathognomonic for AML" (slides 31, 36); "20% blast in your bone marrow" (slide 38); bone marrow biopsy and flow cytometry are "your backbone testing" (slide 36). Played down: the FAB table (slide 33) and the secondary-AML subgroup modifiers (slide 38). Slide emphasis: Auer rods confirm myeloid etiology (underlined); secondary AML poor outcome, gum involvement, fit vs unfit therapy, allogeneic transplant IF remission (bold).

Name of Condition
Acute myeloid leukemia (AML) Slides 30–31
Definition
A leukemia originating with the myeloid progenitor/stem cells: very immature cells with a rapid ability to proliferate; ★ Auer rods are pathognomonic; defined by myeloid blasts >= 20% (certain genetic mutations: 10% or higher) Slides 31, 38
Etiology (cause)
Multiple subtypes by initial mutation and stage of maturation; tremendous cytogenetic and mutational variety, so risk is favorable, intermediate or poor. Secondary AML: arising from another myeloid neoplasm (myelodysplastic syndrome (MDS), myeloproliferative neoplasm (MPN), others) or after treatment of another cancer, with poor outcomes. Historically ~8 FAB subtypes (M0-M7), now 18 by WHO Slides 32–33
Epidemiology (who)
Mostly adults, particularly older adults (>60 years old); unusual in children outside of neonates; male gender Slide 31
Risk Factors
Prior high-dose radiation; benzene, petroleum, certain chemotherapies (alkylators); HIV; Down syndrome, Fanconi anemia, others, ?family history; age over 60; male gender; prior MDS or MPN; prior cancer therapy Slides 34, 38
Pathology
FAB: M0 undifferentiated, M1 minimal maturation, M2 with maturation, M3 acute promyelocytic (APL), M4 acute myelomonocytic, M5 acute monocytic, M6 acute erythroid, M7 acute megakaryocytic. M4 and M5 tend to have more extramedullary involvement; erythroid and megakaryocytic leukemias are very rare. Auer rods are fused lysosomes Slides 32–33, 36
Clinical Manifestation
Symptoms of excess blast production, immune dysfunction and infections. Anemia: fatigue, weakness, lightheadedness, shortness of breath, pale skin. Thrombocytopenia: bruising (often petechiae or purpura), bleeding. Infections. B-symptoms: weight loss, fever, night sweats. Myelomonocytic and monocytic subtypes may have gum involvement (hyperplasia) or extramedullary disease Slide 35
Diagnosis
Labs: anemia, thrombocytopenia, white count often elevated but may be low; unlike ALL, > 200K is rare, and all > 100K need emergent leukapheresis. Confirmed by ★ flow cytometry and bone marrow biopsy (flow differentiates it from ALL); ★ morphology showing Auer rods confirms myeloid etiology; counts, electrolytes, coagulation, mutation sequencing, lumbar puncture. ★ Myeloid blasts >= 20% (10% or higher with certain genetic mutations); cytogenetics and mutations for prognosis; AML with prior MDS or MPN and therapy-related AML = secondary AML. Differential: ALL, CML, MDS, myeloproliferative disorders; pancytopenia of infection, aplastic anemia, nutritional deficiency, drugs (flow shows AML is clonal) Slides 35–38
Treatment/Therapy
Fit patients: intensive chemotherapy, often cytarabine + anthracycline (7+3). Unfit patients: low-intensity therapy, frequently hypomethylating agents +/- a BCL-2 inhibitor (venetoclax). Allogeneic stem cell transplant for most intermediate- and high-risk patients IF able to achieve remission. Referral to and management by a hematologist/oncologist (ideally a leukemia specialist); admission for work-up and treatment; life-long surveillance; clinical trials Slides 40, 42
Mortality ★
Frequent relapse and high treatment-related mortality; overall 48% alive at 1 year, about 25-30% at 5 years; highest for favorable risk (about 2/3 at 5 years) and younger patients; over 70 only 5% at 5 years; adverse risk or secondary AML about 10% Slide 41
Acute promyelocytic leukemia (APL)★ Professor emphasized1 not covered

★ Said: "The thing I want you to remember about APL, bleeding, DIC, coagulopathy, and that it does not need chemotherapy. ATRA and arsenic are the treatments for APL" (slide 43). Slide emphasis: DIC and bleeding, arsenic trioxide and ATRA, >90% cure (bold). PML-RARA was not said aloud.

Name of Condition
Acute promyelocytic leukemia (APL) Slide 43
Definition
A rare AML subtype (FAB M3) caused by arrested differentiation at the promyelocyte Slides 32, 43
Etiology (cause)
Translocation of chromosomes 15 and 17, fusing the PML-RARA genes Slide 43
Epidemiology (who)
Rare AML subtype; otherwise not covered in the lecture Slide 43
Risk Factors
Not covered in the lecture
Pathology
Arrested differentiation at the promyelocyte; t(15;17) PML-RARA fusion Slide 43
Clinical Manifestation
★ Frequently presents with emergent complications, including DIC (disseminated intravascular coagulation) and bleeding Slide 43
Diagnosis
The AML work-up (flow cytometry, bone marrow biopsy, coagulation); t(15;17) PML-RARA Slides 36, 43
Treatment/Therapy
★ Unique treatment approach: arsenic trioxide and all-trans-retinoic acid (ATRA) Slide 43
Mortality ★
High early mortality; if the initial presentation is survived, excellent prognosis (>90% cure rate) Slide 43
Myelodysplastic syndrome (MDS)★ Professor emphasized

★ Said: the blast drill on slide 47 ("If it's 10%, is it leukemia? No. If it's 15%, leukemia? No."; 20% = leukemia). Slide emphasis: defined by dysplasia; cytopenias, frequently anemia; low risk defined by anemia; more common in men; low risk + anemia = erythropoiesis-stimulating agents; the only cure is allogeneic transplant (bold).

Name of Condition
Myelodysplastic syndrome (MDS) Slides 44–45
Definition
A group of myeloid malignancies defined by dysplasia (abnormal appearing) of myeloid cells, distorting hematopoiesis, with immune dysregulation and genomic changes (mutations) Slide 45
Etiology (cause)
Often evolves from milder abnormal stem cell clones (clonal hematopoiesis) until the dysplasia of MDS develops; often idiopathic; sometimes prior chemotherapy or radiation Slide 46
Epidemiology (who)
Older population (median 70 years); more common in men Slide 46
Risk Factors
Older age; male sex; prior chemotherapy or radiation; often idiopathic Slide 46
Pathology
Typically a hypercellular marrow, but the cells are not functional. Low risk MDS is commonly defined by anemia with a low risk of AML progression; very high-risk MDS has elevated blasts and substantial overlap with AML Slide 46
Clinical Manifestation
Many are asymptomatic and found incidentally. Fatigue, weakness, pale skin from anemia; infections from ineffective white cells; bleeding from thrombocytopenia Slides 45, 47
Diagnosis
Most frequently anemia; neutropenia; occasional thrombocytopenia; neutrophils with morphological abnormalities; often red cell abnormalities (multinucleated or hyperplastic); ★ higher risk MDS may have blasts but < 20% (otherwise AML) Slide 47
Treatment/Therapy
Highly dependent on blood counts, risk status and mutations. ★ Low risk + anemia: erythropoiesis-stimulating agents (ESA) and red cell transfusions as needed; neutropenia: myeloid growth factors (careful not to overstimulate blasts); higher risk: chemotherapy or hypomethylating agents; ★ the only curative therapy is allogeneic stem cell transplant, but high risk and a limited role Slide 48
Mortality ★
Highly variable by risk: lower risk median survival > 5 years with very low risk of AML; very high risk median overall survival 9 months and > 80% risk of AML within 5 years. Low risk patients often have complications from anemia, bleeding and/or infections; the goal of treatment is quality of life. Prior MDS makes AML secondary (poor outcome) Slides 49, 38
Polycythemia vera★ Professor emphasized

★ Said: "Polycythemia vera, JAK2 mutation, you may come across this on your testing, you might wanna remember that or write that down" (slide 52). Slide emphasis: classic pruritus with warm baths or showers (bold). Not said aloud: the 14-year survival, ~5% transformation, smoking cessation. Secondary polycythemia (a syllabus item) is not on the deck.

Name of Condition
Polycythemia vera Slides 50–52
Definition
A myeloproliferative neoplasm (a rare myeloid malignancy with atypical proliferation of mature cell lines): over-production of red blood cells, increasing blood viscosity Slide 51
Etiology (cause)
★ Commonly the result of a JAK2 mutation Slide 52
Epidemiology (who)
Myeloproliferative neoplasms are rare; otherwise not covered in the lecture Slide 51
Risk Factors
JAK2 mutation; otherwise not covered in the lecture Slide 52
Pathology
Over-production of red blood cells (increased blood viscosity) Slide 51
Clinical Manifestation
Usually non-specific: fatigue, headaches, blurry vision. ★ Classic: pruritus with warm baths or showers Slide 52
Diagnosis
JAK2 mutation; otherwise not covered in the lecture Slide 52
Treatment/Therapy
Phlebotomy, hydroxyurea; refer to a hematologist; advise to stop smoking Slide 52
Mortality ★
Complications: thrombosis, splenomegaly, bleeding. Prognosis excellent: estimated survival of 14 years; leukemic transformation rare (~5% of cases) Slide 52
Myelofibrosis1 not covered
Name of Condition
Myelofibrosis Slide 53
Definition
A myeloproliferative neoplasm: over-production of mature myeloid cell lines, eventually causing fibrosis of the marrow; the most aggressive of the MPNs Slides 51, 53
Etiology (cause)
Abnormal JAK-STAT pathway mutations, causing elevated cytokines and marked excess proliferation of all myeloid cell lines Slide 53
Epidemiology (who)
Myeloproliferative neoplasms are rare; otherwise not covered in the lecture Slide 51
Risk Factors
JAK-STAT pathway mutations; otherwise not covered in the lecture Slide 53
Pathology
Elevated cytokines, excess proliferation of all myeloid cell lines, then fibrosis of the marrow Slide 53
Clinical Manifestation
Usually non-specific: fatigue and abdominal symptoms from splenomegaly (pain, early satiety and/or bloating); night sweats, fever, weight loss also common Slide 53
Diagnosis
Not covered in the lecture
Treatment/Therapy
Often targeted inhibitors (JAK inhibitors), which are palliative; refer to a hematologist upon diagnosis Slide 53
Mortality ★
Complications: severe splenomegaly, portal hypertension, bleeding, progression to secondary AML. Prognosis highly variable: low risk can live 10-15 years; high risk often survive less than 2 years Slide 53
Essential thrombocythemia
Name of Condition
Essential thrombocythemia Slide 54
Definition
A myeloproliferative neoplasm: over-production of platelets Slide 51
Etiology (cause)
Often gene mutations in the JAK-STAT pathway, causing overproduction of platelets; rarely inherited Slide 54
Epidemiology (who)
Myeloproliferative neoplasms are rare; otherwise not covered in the lecture Slide 51
Risk Factors
JAK-STAT pathway gene mutations; rarely inherited Slide 54
Pathology
Bleeding despite high platelets can occur from acquired von Willebrand factor deficiency (a shortage of the factor at the site of injury) Slide 54
Clinical Manifestation
Mostly asymptomatic, but may present with clotting (headaches, fatigue, paresthesias or vision changes) or bleeding Slide 54
Diagnosis
High platelets; otherwise not covered in the lecture Slide 54
Treatment/Therapy
★ Aspirin, hydroxyurea, or other agents to reduce clotting risk; refer to a hematologist; advise to stop smoking Slide 54
Mortality ★
Complications: clotting, including CVA (stroke) and MI (myocardial infarction). Prognosis excellent: generally a normal life span with appropriate management Slide 54
Chronic myelogenous leukemia (CML)★ Professor emphasized

★ Said: she walked through the slide 64 milestones (optimal BCR-ABL1 under 10% at 3 months, under 1% at 6, under 0.1% at 12) and shows the table to nearly every patient. Not taught aloud: the slide 61 differential. Slide emphasis: BCR-ABL / Philadelphia chromosome and "now largely a chronic disorder" (bold); splenomegaly and bone marrow biopsy + PCR for BCR-ABL1 (underlined); the phases and tyrosine kinase inhibitors (bold). Out loud she called chronic phase "five to 6% blast" (slide: <5%).

Name of Condition
Chronic myelogenous leukemia (CML) Slides 55–56
Definition
A leukemia originating from hematopoietic stem cells that produces increased numbers of granulocytes (more mature than blasts); historically progressed from a chronic condition to acute leukemia in ~4-6 years Slide 56
Etiology (cause)
★ Hallmark BCR-ABL mutation from fusion of chromosomes 22 and 9: the Philadelphia chromosome. The translocation attaches the BCR gene to the ABL1 gene; the BCR-ABL fusion protein is a functional enzyme that promotes cell proliferation and reduces apoptosis (the cell "can't turn off" and constantly divides) Slides 56–57
Epidemiology (who)
15-20% of all leukemias; median age 45-55 years; either sex, slightly more common in men Slide 58
Risk Factors
May be more common in radiation bomb victims (Japan); no other identified risk factors Slide 58
Pathology
Marrow: marked granulocytic proliferation and myelocytes in chronic phase. Phases: chronic (stable), early proliferative, no or few blasts (<5%), 85-90% of presentations, excellent prognosis; accelerated, often 10-19% blasts, dysplastic granulocytes and fibrosis, significant splenomegaly, ~4-5%; blast phase/crisis, behaves as an acute leukemia (usually AML-like), unique chromosomal and mutational abnormalities, ~1-2% Slides 60, 62
Clinical Manifestation
~50% asymptomatic at diagnosis (found from leukocytosis on a complete blood count). Anemia: fatigue, weakness, lightheadedness, shortness of breath. ★ Abdominal swelling or discomfort from splenomegaly. B-symptoms: weight loss, fever, night sweats, loss of appetite Slide 59
Diagnosis
Labs: ★ marked leukocytosis, thrombocytosis, anemia; white count often > 100K and up to 500K; platelets usually elevated; very low blasts unless accelerated or blast phase. ★ Confirmed by bone marrow biopsy and PCR for the BCR-ABL1 mutation: PCR in a patient with marked granulocytosis confirms the diagnosis and monitors treatment response; flow cytometry for lineage and mutation analysis. Differential: other myeloproliferative disorders, namely myelofibrosis (the slide also names CMML, never expanded): in CML red cell morphology is normal and the hematocrit is not elevated; definitive when BCR/ABL1 is positive on PCR. Reactive leukocytosis of infection: no splenomegaly, white count usually < 50K, BCR/ABL1 negative Slides 59–61
Treatment/Therapy
★ Tyrosine kinase inhibitors are the hallmark of therapy for chronic phase CML (6 approved agents). Milestones (BCR-ABL1): optimal < 10% at 3 months, < 1% at 6 months, < 0.1% at 12 and > 18 months; warning > 10% at 3 months, 1-10% at 6, 0.1-1% at 12 and > 18; failure > 10% at 6 months, > 1% at 12 and > 18; < 0.01% after 18 months = treatment-free remission range. Major molecular response for 2 years may allow stopping (recurrence in 50%; most recapture deep responses). Advanced CML (accelerated or blast phase) has different considerations; blast phase needs AML-like regimens (poor responses to TKIs). Allogeneic stem cell transplant for young healthy patients with TKI resistance or advanced stage. Referral to and management by a hematologist; treatment for life unless sustained major molecular remission x 2 years; clinical trials for advanced phase Slides 62–64, 66
Mortality ★
Once fatal; ★ now largely a chronic disorder: most patients live normal lives on TKIs or stay off therapy after sustained major molecular response. Accelerated or blast phase outcomes remain poor (median survival < 12 months) Slides 56, 65

Lecture 50 · Hematologic Malignancies Part II

Nicole Gannon, PA-C · 14 conditions · source: 50. Hematologic Malignancies Part II - Gannon.pptx

Note: Built from the slides only. Ms. Gannon's spoken flags (recording, 18 November, parts 3-4) lead each note; the stars also mark the slides' own bold and underline. Her one spoken correction: the slides' 50% cure for aggressive lymphoma (slide 30) and diffuse large B-cell lymphoma (slide 34) - she said closer to 70%, so no cure percentage is given for them. Slide 41 is titled "Management of NHL" but teaches Hodgkin. "Most common leukemia" is not keyed (slides 4 and 6 against Lecture 49 slide 31). Smoldering myeloma is printed "M-protein > 3 g/dl AND 10-60% plasma cells" (slide 57). The slides give no epidemiology for MGUS or smoldering myeloma and no treatment for MGUS, mantle cell or marginal zone lymphoma beyond the general non-Hodgkin lines.
Chronic lymphocytic leukemia (small lymphocytic lymphoma)★ Professor emphasized

★ Said: "High white count, painless lymphadenopathy, underline, underline, star, star"; flow cytometry is the most important work-up, CD19 + CD5 pathognomonic so no marrow biopsy; Richter transformation "you should highlight"; an isolated white count alone does not equal treatment. Slide emphasis: mature B cells, asymptomatic on routine labs, lymphocytosis >5K, watch and wait.

Name of Condition
Chronic lymphocytic leukemia (small lymphocytic lymphoma) Slides 3, 4
Definition
A proliferative leukemia of ★ mature B-cell lymphocytes in blood, bone marrow, lymph nodes, and spleen; called small lymphocytic lymphoma in the nodes. Rare mature T-cell leukemias are T-cell prolymphocytic leukemia Slide 4
Etiology (cause)
Mutagenesis in mature B cells gives a clonal population; 80% of cases come from loss or addition of chromosomal material in one of four abnormalities: ★ deletion 13q, deletion 11q, trisomy 12, deletion 17p Slide 5
Epidemiology (who)
1% of all new cancer cases in the United States; median age at diagnosis 70 years; twice as common in males; more common in Eastern Europeans and those of Jewish descent Slides 4, 6
Risk Factors
Age (median onset 70); male sex; Eastern European or Jewish descent; no known occupational or environmental risk factors Slide 6
Pathology
A clone of mature B cells coexpressing ★ CD19 and CD5 accumulates in blood, marrow, nodes and spleen; ineffective white cells cause infections, marrow crowding causes anemia and thrombocytopenia Slides 5, 7–8
Clinical Manifestation
★ Frequently diagnosed while asymptomatic on routine blood work; ★ painless lymphadenopathy (50-90%), localized or generalized, firm, mobile; B symptoms (weight loss, night sweats, fevers) in 5-10%; anemia: fatigue; thrombocytopenia: easy bruising, bleeding; infections; splenomegaly (~40%), less commonly hepatomegaly Slide 7
Diagnosis
★ Lymphocytosis (must be >5K; often >100K), frequently anemia; ★ diagnosis confirmed by flow cytometry (clonal B-cell population); absolute lymphocyte count >5K for 3 months, or <5K with lymphadenopathy or other symptoms; coexpression of CD19 and CD5; cytogenetics for prognosis; bone marrow biopsy usually not required. Rai stage (0 asymptomatic lymphocytosis; I + lymphadenopathy; II + organomegaly; III + anemia; IV + thrombocytopenia) from exam and labs. Differential: monoclonal B lymphocytosis (elevated count but <5K with no nodes, organomegaly, cytopenias or symptoms; progresses to chronic lymphocytic leukemia 1-2% per year), atypical lymphocytosis with infection (pertussis), Waldenstrom macroglobulinemia, hairy cell leukemia, lymphomas in leukemic phase Slides 7–10
Treatment/Therapy
★ Watch and wait if asymptomatic until rapid progression (lymphocyte count doubling in <6 months) or disease-related symptoms. Bruton tyrosine kinase inhibitors (ibrutinib, acalabrutinib, zanubrutinib), usually continuous as monotherapy; BCL-2 inhibitor venetoclax combined with monoclonal antibodies for a fixed duration; monoclonal antibodies (rituximab, obinutuzumab, ofatumumab); trend toward combinations. Referral to and management by hematology/oncology; unlikely to need hospitalization; pill therapy (once or twice daily, indefinite) or infusion + pill (time-limited, more intensive) Slides 11, 13
Mortality ★
5-year relative survival ~88% (since 2013); ★ risk of Richter transformation to an aggressive B-cell lymphoma with poor outcomes; many patients will die with chronic lymphocytic leukemia rather than from it; very good long-term prognosis likely Slides 12–13
Non-Hodgkin lymphoma (the group)★ Professor emphasized1 not covered

★ Said: on a test expect HIV, EBV, HTLV-1, H. pylori; excisional biopsy is the key (never trust a negative fine needle aspiration); LDH on every lymphoma; staging by the diaphragm; T cells always worse than B cells. Slide emphasis: 85% B-cell, >2/3 lymphadenopathy, B symptoms, CT or PET.

Name of Condition
Non-Hodgkin lymphoma (the group) Slides 14, 15
Definition
A ★ diverse group of malignancies of lymphoid tissues derived from B cells, T cells, or NK cells that present frequently with lymphadenopathy; ★ 85% B-cell, 15% T-cell or NK-cell; ranges from very aggressive (Burkitt, diffuse large B-cell, T-cell leukemia/lymphoma) to indolent (follicular, marginal zone, chronic lymphocytic leukemia/small lymphocytic lymphoma) Slide 15
Etiology (cause)
Immunosuppression, autoimmunity, chronic infection and environmental exposure (the risk factor list); subtype-defining genes: t(14;18) BCL-2 (follicular), cyclin D1 t(11;14) (mantle cell), MYC (Burkitt), MYD88 (lymphoplasmacytic) Slides 16–18, 20, 31
Epidemiology (who)
4% of all new cancer diagnoses in the United States; higher incidence in White individuals and developed countries; male gender Slides 15, 23
Risk Factors
Male gender; immunosuppression (prior immunotherapy, chemotherapy, radiation, malignancy; prior transplantation); autoimmune conditions (lupus, Sjogren, celiac); Crohn's; environmental exposures including DDT (farming); chronic infections: H. pylori gastritis (MALT), HTLV-1, hepatitis C, HIV, Epstein-Barr virus, Lyme disease, HHV-8; family history Slide 23
Pathology
Not covered in the lecture
Clinical Manifestation
★ Peripheral lymphadenopathy in >2/3; ★ B symptoms (weight loss, night sweats, fever of unknown origin), rash, hypersensitivity reactions, fatigue, pruritus, malaise, ascites, effusion; about half develop extranodal disease; CNS lymphoma: headaches, lethargy, neurologic defects; primary mediastinal B-cell lymphoma: large mediastinal mass, cough, abnormal chest X-ray Slide 24
Diagnosis
★ Excisional lymph node biopsy for significant enlargement (2 cm), persistent, progressive; avoid fine needle aspiration (architecture needed; may miss the diagnosis); ★ imaging (usually CT or PET) to characterize and stage; complete blood count (cytopenias with marrow involvement), chemistries (electrolytes, rule out tumor lysis syndrome), LDH (rapid proliferation); bone marrow biopsy; lumbar puncture for high-grade lymphomas including Burkitt. Lugano staging (modified Ann Arbor): 1 single node region or organ; 2 two or more regions same side of the diaphragm; 3 above and below the diaphragm; 4 widespread, multiple organs Slides 25–26
Treatment/Therapy
Highly dependent on subtype: single node, non-aggressive: radiation; low-grade B-cell: rituximab (anti-CD20) if treatment required +/- chemotherapy if extensive; aggressive B-cell: multi-drug chemotherapy such as R-CHOP (rituximab, cyclophosphamide, vincristine, doxorubicin, prednisone); T-cell: CHOP minus rituximab (no CD20 on T cells). Hematologist referral, ideally a lymphoma expert; hospitalization for aggressive disease with electrolyte abnormalities, otherwise outpatient; drink plenty of fluids and take allopurinol on starting treatment Slides 27, 34
Mortality ★
★ Tumor lysis syndrome (medical emergency); infections, bleeding, anemia, electrolyte abnormalities, diarrhea with all chemotherapy. Indolent lymphomas incurable but survival often 10-15+ years, with risk of progression to aggressive lymphoma; aggressive lymphomas often treatable and curable with chemotherapy, 5-year survival 60-70% (the slide's cure percentage was corrected out loud upward, to about 70%); T-cell respond less well than B-cell. Poor prognosis: age >60, extranodal sites, ECOG performance status >2, stage III or IV, elevated LDH Slides 28–30
Follicular lymphoma2 not covered
Name of Condition
Follicular lymphoma Slide 16
Definition
The most common indolent histology of non-Hodgkin lymphoma Slide 16
Etiology (cause)
Chromosomal translocation t(14;18) places the BCL-2 gene on chromosome 14, preventing cell death Slide 16
Epidemiology (who)
Not covered in the lecture
Risk Factors
Not covered in the lecture
Pathology
Microscopy often shows clusters of packed follicles Slide 16
Clinical Manifestation
Typically indolent: waxing and waning painless lymphadenopathy Slide 16
Diagnosis
Microscopy: clusters of packed follicles; excisional biopsy and staging as for non-Hodgkin lymphoma Slide 16
Treatment/Therapy
Frequently no treatment required (watch and wait); intermittent low-intensity therapy if symptomatic; high-risk follicular lymphoma may need more aggressive chemotherapies and immunotherapies Slide 16
Mortality ★
Often no treatment or only intermittent treatment, but incurable; indolent lymphomas survive often 10-15+ years with risk of progression to aggressive lymphoma Slides 30, 34
Marginal zone lymphoma (including MALT lymphoma)3 not covered
Name of Condition
Marginal zone lymphoma (including MALT lymphoma) Slide 17
Definition
Indolent non-Hodgkin lymphomas, 5-17% of all non-Hodgkin lymphoma, most commonly the extranodal subtype; subtypes: extranodal or mucosa-associated lymphoid tissue (MALT, most common), nodal marginal zone, splenic marginal zone Slide 17
Etiology (cause)
Gastric MALT: 2/3 of cases associated with H. pylori; splenic marginal zone associated with hepatitis C Slide 17
Epidemiology (who)
5-17% of non-Hodgkin lymphoma; more common in older adults Slide 17
Risk Factors
H. pylori gastritis; hepatitis C; older age Slides 17, 23
Pathology
MALT involves organs with mucosa: gastrointestinal tract, eyes, lungs Slide 17
Clinical Manifestation
Not covered in the lecture
Diagnosis
Not covered in the lecture
Treatment/Therapy
Not covered in the lecture
Mortality ★
Indolent lymphomas: incurable but survival often 10-15+ years Slide 30
Lymphoplasmacytic lymphoma (Waldenstrom macroglobulinemia)★ Professor emphasized2 not covered

★ Said: farming, pesticides - "kind of always choose that on the test if you see it".

Name of Condition
Lymphoplasmacytic lymphoma (Waldenstrom macroglobulinemia) Slide 18
Definition
An indolent lymphoma, also known as Waldenstrom macroglobulinemia, affecting lymphoplasmacytoid cells and plasma cells (terminally differentiated B cells) Slide 18
Etiology (cause)
MYD88 mutation frequently found (~90% of cases) Slide 18
Epidemiology (who)
Not covered in the lecture
Risk Factors
Genetic (familial); environmental (farming, pesticides) Slide 18
Pathology
Excess IgM production: a large antibody that causes hyperviscosity Slide 18
Clinical Manifestation
Hyperviscosity: blurred vision, headache, rarely stroke (cerebrovascular accident) Slide 18
Diagnosis
MYD88 mutation; IgM monoclonal protein (different pathophysiology and treatment from myeloma) Slides 18, 49
Treatment/Therapy
Not covered in the lecture
Mortality ★
Good prognosis overall; relative 5-year survival 78% Slide 18
Diffuse large B-cell lymphoma1 not covered
Name of Condition
Diffuse large B-cell lymphoma Slide 19
Definition
An aggressive B-cell lymphoma, the most common non-Hodgkin lymphoma in adults, with many subtypes by location, mutations and infectious associations Slide 19
Etiology (cause)
Many subtypes based on location, mutations, and infectious associations Slide 19
Epidemiology (who)
Most common non-Hodgkin lymphoma in adults Slide 19
Risk Factors
Older age, family history, autoimmune conditions, infections, environmental Slide 19
Pathology
Not covered in the lecture
Clinical Manifestation
Fast-growing mass/swelling and/or B symptoms (fever, fatigue, night sweats, weight loss) Slide 19
Diagnosis
Excisional biopsy, CT or PET staging and labs as for non-Hodgkin lymphoma Slides 25–26
Treatment/Therapy
Aggressive B-cell lymphoma: multi-drug chemotherapy such as R-CHOP (rituximab, cyclophosphamide, vincristine, doxorubicin, prednisone) Slide 27
Mortality ★
Often treatable and curable with multi-agent chemotherapy (slide 34 prints a cure percentage that she corrected out loud: "more closely to 70%"); aggressive lymphomas: 5-year survival 60-70%; tumor lysis syndrome risk Slides 30, 34
Mantle cell lymphoma3 not covered
Name of Condition
Mantle cell lymphoma Slide 20
Definition
A rare subtype of non-Hodgkin lymphoma identified by the cyclin D1 gene translocation t(11;14); typically aggressive, though an indolent variant has been described Slide 20
Etiology (cause)
Cyclin D1 gene translocation t(11;14) Slide 20
Epidemiology (who)
5% of all non-Hodgkin lymphoma; more common in men; median age 60-70 years Slide 20
Risk Factors
Male sex; age 60-70 Slide 20
Pathology
Not covered in the lecture
Clinical Manifestation
Not covered in the lecture
Diagnosis
Cyclin D1 translocation t(11;14) Slide 20
Treatment/Therapy
Not covered in the lecture
Mortality ★
Median survival from under 2 years to over 9, depending on the aggressive or indolent variant Slide 20
T-cell lymphomas, including cutaneous T-cell lymphoma (mycosis fungoides, Sezary syndrome)1 not covered
Name of Condition
T-cell lymphomas, including cutaneous T-cell lymphoma (mycosis fungoides, Sezary syndrome) Slides 21–22
Definition
A diverse group of non-Hodgkin lymphomas with many subtypes: peripheral T-cell lymphoma, not otherwise specified (most common, 1/3), nodal T-cell, anaplastic large cell (aggressive), adult T-cell leukemia/lymphoma (very aggressive), intestinal, extranodal NK/T-cell (often nasal), hepatosplenic; cutaneous T-cell lymphoma = mycosis fungoides, with a more aggressive form, Sezary syndrome Slides 21–22
Etiology (cause)
Adult T-cell leukemia/lymphoma is associated with HTLV-1 Slide 21
Epidemiology (who)
15% of non-Hodgkin lymphoma are T-cell or NK-cell; adult T-cell leukemia/lymphoma more common in the Caribbean, Central and South America Slides 15, 21
Risk Factors
HTLV-1 infection Slides 21, 23
Pathology
Mycosis fungoides often has no visceral involvement Slide 22
Clinical Manifestation
Mycosis fungoides: skin lesions that resemble fungal infections, progressing to nodular lesions that may ulcerate; Sezary syndrome: widespread, red, itchy rash (erythroderma) with severe pruritus and diminished quality of life; extranodal NK/T-cell lymphoma often affects the nasal region Slides 21–22
Diagnosis
Not covered in the lecture
Treatment/Therapy
T-cell lymphomas: CHOP-type regimens minus rituximab (no CD20 expression on T cells); cutaneous T-cell lymphoma: treatment focused on the skin manifestations Slides 22, 27
Mortality ★
T-cell lymphomas respond less well than B-cell lymphomas; adult T-cell leukemia/lymphoma very aggressive Slides 21, 30
Burkitt lymphoma★ Professor emphasized

★ Said: "If a pathologist ever says starry sky, you think Burkitt's ... you'll definitely see that on a test"; endemic region sub-Saharan Africa, strongly associated with EBV. Slide emphasis: prompt treatment with emergent referral; tumor lysis.

Name of Condition
Burkitt lymphoma Slides 31–33
Definition
A very aggressive lymphoma variant with three types: endemic, sporadic, immunodeficiency-associated Slide 31
Etiology (cause)
Associated with MYC gene upregulation, resulting in stimulated cell growth and division; endemic type strongly associated with Epstein-Barr virus; immunodeficiency type associated with HIV/AIDS Slides 31–32
Epidemiology (who)
Endemic: largely sub-Saharan Africa and New Guinea; sporadic: United States and Western Europe, more in males, almost always under age 35; immunodeficiency-associated: HIV/AIDS Slide 32
Risk Factors
Epstein-Barr virus (endemic); HIV/AIDS; male sex and age under 35 (sporadic) Slide 32
Pathology
★ "Starry sky" appearance: sheets of lymphoma with benign macrophages clearing out dying lymphoma cells; extremely fast doubling time Slides 32–33
Clinical Manifestation
Very rapidly growing, often painless swelling (visible change within one day); commonly B symptoms (fever, night sweats, weight loss) Slide 31
Diagnosis
Pathology: starry sky; high-grade lymphomas including Burkitt require a lumbar puncture Slides 25, 32
Treatment/Therapy
★ Prompt treatment with emergent referral to a hematologist; rapid transfer of care; multi-agent chemotherapy; caution starting therapy because of tumor lysis syndrome Slides 33–34
Mortality ★
Excellent long-term prognosis if identified and treated early: >90% in children, 50-90% in adults; ★ tumor lysis syndrome, which can occur spontaneously Slides 28, 33
Hodgkin lymphoma★ Professor emphasized

★ Said: Reed-Sternberg cells - "automatically think of Hodgkin's"; ABVD + painless lymphadenopathy = Hodgkin; node pain after alcohol as a test clue. Slide emphasis: bimodal, EBV 40-50%, painless cervical nodes, >90% alive at 5 years.

Name of Condition
Hodgkin lymphoma Slides 35, 36
Definition
A type of B-cell lymphoma characterized by few malignant cells (★ Reed-Sternberg cells: binucleated, neoplastic B cells) among numerous immune effector cells; contiguous, orderly spread through lymph nodes Slide 36
Etiology (cause)
Epstein-Barr virus suspected (identified in 40-50% of cases); others including HIV, HHV-6, tuberculosis Slide 37
Epidemiology (who)
~10-15% of all lymphoma diagnoses worldwide; ★ bimodal incidence: adults in their 20s and adults >60 Slides 36–37
Risk Factors
Same-sex siblings have a 10x increased risk; ★ Epstein-Barr virus (40-50%); HIV, HHV-6, tuberculosis Slide 37
Pathology
Reed-Sternberg cells; classical Hodgkin lymphoma expresses CD15 and CD30; spreads contiguously Slides 36, 39
Clinical Manifestation
★ Painless asymptomatic lymphadenopathy (70%), ★ usually cervical, could be supraclavicular or mediastinal; ★ pain may worsen with alcohol consumption; mediastinal mass on chest X-ray; splenomegaly (~30%), sometimes hepatomegaly; pruritus, may be very intense Slide 38
Diagnosis
Excisional lymph node biopsy (avoid fine needle aspiration); classical type CD15 and CD30; chest X-ray rules out mediastinal mass/adenopathy; complete blood count, chemistries (rule out tumor lysis), LDH; bone marrow biopsy; Lugano staging (modified Ann Arbor) Slides 39–40
Treatment/Therapy
Early stage I and IIA: short course of chemotherapy (★ ABVD historically); bulky stage I or II or B symptoms: chemotherapy + radiation; stage III or IV: chemotherapy. ABVD: doxorubicin (Adriamycin), bleomycin, vinblastine, dacarbazine; new agents replacing bleomycin because of pulmonary toxicities. Relapse after first line: allogeneic stem cell transplant Slides 41–42
Mortality ★
★ Generally curable, >90% alive at 5 years; inferior results with older patients, bulky disease, lymphocyte-depleted or mixed-cellularity subtypes; delayed toxicities: myelodysplastic syndrome, secondary leukemia, other cancers Slide 42
Multiple myeloma★ Professor emphasized

★ Said: CRAB - "it will 100% be on a test in some form"; myeloma needs only 10% marrow plasma cells (vs 20% blasts in acute leukemia); remember Bence Jones protein; "we don't use staging too much in myeloma". Slide emphasis: diagnosis line, 3- or 4-drug regimen, most relapse, incurable.

Name of Condition
Multiple myeloma Slides 43, 44
Definition
A malignant, incurable clonal disorder of plasma cells (terminally differentiated B cells), at the far end of the plasma cell disorder spectrum from MGUS Slide 44
Etiology (cause)
Clonal evolution of plasma cells produces a single, overproduced antibody type, most commonly IgG Slide 45
Epidemiology (who)
10% of all hematologic malignancies; most diagnoses over age 65; African Americans at higher risk Slides 44, 46
Risk Factors
Age (most over 65); African American race; family history; prior MGUS or smoldering myeloma; environmental exposures (radiation, chemical, occupational) Slide 46
Pathology
Activates osteoclasts, releasing calcium into the bloodstream; renal dysfunction from light chain and calcium phosphate deposition; anemia from renal dysfunction and marrow involvement; osteolytic "punched out" lesions Slides 45, 48
Clinical Manifestation
★ CRAB: calcium (hypercalcemia: constipation, increased thirst, urinary frequency, nausea); renal insufficiency (swelling); anemia (fatigue, shortness of breath); bone lesions/pain (back, chest, pelvis). May be asymptomatic with certain lab findings (SLiM: bone marrow plasma cells >=60%, light chain ratio >100:1, MRI >=2 lesions). Higher risk of infections; also amyloidosis, hyperviscosity, polyneuropathies Slide 47
Diagnosis
★ >=10% bone marrow plasma cells or biopsy-proven plasmacytoma + 1 or more CRAB feature; monoclonal protein on serum protein electrophoresis is characteristic; urine ★ Bence Jones protein; complete blood count, metabolic/electrolyte panel, 24-hour urine protein electrophoresis, bone marrow biopsy with flow, kappa/lambda light chain ratio, beta-2 microglobulin, whole-body CT for bone lesions. R-ISS: I beta-2 microglobulin <3.5 mg/L, albumin >=3.5 g/dL, standard-risk chromosomes, normal LDH; II not I or III; III beta-2 microglobulin >=5.5 mg/L, high-risk chromosomes (del 17p, t(4;14), t(14;16)), high LDH; prognostic only. Differential: smoldering myeloma, MGUS, Waldenstrom (IgM), chronic lymphocytic leukemia, non-Hodgkin lymphoma, amyloidosis, reactive hypergammaglobulinemia (cirrhosis, chronic inflammation) Slides 49–51
Treatment/Therapy
★ Goal: prolonged remissions to improve survival and quality of life; ★ newly diagnosed: 3- or 4-drug regimen with a proteasome inhibitor and immunomodulatory drug backbone with steroids; autologous transplant (and maintenance after) if a candidate; continuous therapy at relapse; CAR-T, bispecifics, antibody-drug conjugates for relapsed myeloma. Hematologist/oncologist, ideally a myeloma expert; lifelong treatment and follow-up Slides 52–53, 55
Mortality ★
5-year relative survival ~60% (2018-2022); ★ each line of therapy has shorter remissions; incurable/fatal; ★ most patients relapse; newly diagnosed patients today may survive >10 years Slides 53–54
Monoclonal gammopathy of undetermined significance (MGUS)4 not covered
Name of Condition
Monoclonal gammopathy of undetermined significance (MGUS) Slides 44, 56
Definition
A clonal, low-level plasma cell disorder: M-protein <3 g/dL, clonal bone marrow plasma cells <10%, no myeloma-defining characteristics; by definition asymptomatic (the slide title says "unknown significance") Slide 56
Etiology (cause)
Not covered in the lecture
Epidemiology (who)
Not covered in the lecture
Risk Factors
Not covered in the lecture
Pathology
Clonal proliferation of plasma cells at a low level Slide 56
Clinical Manifestation
Asymptomatic by definition Slides 44, 56
Diagnosis
M-protein <3 g/dL; clonal bone marrow plasma cells <10%; no myeloma-defining characteristics Slide 56
Treatment/Therapy
Not covered in the lecture
Mortality ★
Risk of progression to myeloma ~1% per year; a risk factor for multiple myeloma Slides 46, 56
Smoldering myeloma3 not covered
Name of Condition
Smoldering myeloma Slides 44, 57
Definition
An intermediate-stage clonal plasma cell disorder: M-protein >3 g/dL AND 10-60% bone marrow plasma cells, with no myeloma-defining events Slide 57
Etiology (cause)
Not covered in the lecture
Epidemiology (who)
Not covered in the lecture
Risk Factors
Not covered in the lecture
Pathology
Intermediate stage between MGUS and myeloma; a more indolent process Slides 49, 57
Clinical Manifestation
No myeloma-defining events (anemia, bone lesions, renal failure, etc.); no symptoms Slide 57
Diagnosis
M-protein >3 g/dL and 10-60% bone marrow plasma cells without anemia, bone lesions or renal failure Slide 57
Treatment/Therapy
Typically does not require treatment (often monitored); may consider early intervention for some subgroups Slides 49, 57
Mortality ★
★ Progression approximately 10% per year; some high-risk groups >50% risk of progression within 2 years; a risk factor for multiple myeloma Slides 46, 57
Tumor lysis syndrome★ Professor emphasized

★ Said: "Very important to know this ... an oncologic emergency. You need to know it, you need to recognize it for your testing"; high potassium, high phosphorus, high uric acid (she added low calcium, not on the slide); fluids and allopurinol.

Name of Condition
Tumor lysis syndrome Slide 28
Definition
A ★ medical emergency due to rapid tumor breakdown and release of cellular products (potassium, phosphorus, uric acid) Slide 28
Etiology (cause)
Rapid tumor breakdown, spontaneously in highly aggressive lymphomas (Burkitt) or on starting therapy Slides 28, 33
Epidemiology (who)
Aggressive lymphoma (Burkitt); also acute lymphoblastic and acute myeloid leukemia with marked leukocytosis Slide 28
Risk Factors
Highly aggressive lymphoma; starting chemotherapy Slide 28
Pathology
Release of potassium, phosphorus and uric acid; uric acid and calcium phosphate crystals precipitate in the renal tubules Slide 28
Clinical Manifestation
Arrhythmia from hyperkalemia; acute renal failure Slide 28
Diagnosis
Chemistries (electrolytes) in the lymphoma work-up to rule it out Slide 25
Treatment/Therapy
★ Requires aggressive IV fluid hydration; anticipate in aggressive lymphoma: allopurinol (hypouricemic agent) and fluids in advance; patients drink plenty of fluids and take allopurinol Slides 28, 34
Mortality ★
Largest risk: hyperkalemia leading to arrhythmia and potential death; acute renal failure Slide 28